Bio-Path To Uplist Shares, TKMR Gets A Shot In The Arm, Two To Go For NAVB

(RTTNews) - Bio-Path Holdings Inc. (BPTH.OB) has received approval to uplist its shares to the NASDAQ Capital Market. Accordingly, the stock will commence trading on the NASDAQ Capital Market under the symbol BPTH from March 10, 2014.

CytRx Corp. (CYTR) is all set to initiate a pivotal global phase III trial of Aldoxorubicin as second-line treatment for soft tissue sarcoma this quarter. The company expects data readouts in the second half of the year from the ongoing phase II clinical trial of Aldoxorubicin in glioblastoma as well as updated results from its global phase IIb trial of Aldoxorubicin in first-line soft tissue sarcoma.

CYTR closed Wednesday's trading at $5.94, down 3.57%.

La Jolla Pharmaceutical Co. (LJPC) will be presenting an update on its phase II clinical study of GCS-100 for the treatment of chronic kidney disease at the 26th Annual ROTH Conference on March 10, 2014.

LJPC closed Wednesday's trading 3.41% higher at $7.89.

Merck & Co. Inc.'s (MRK) investigational hepatitis C treatment regimen of MK-5172/MK-8742 has shown robust anti-HCV activity in people living with HIV/HCV co-infection in an ongoing phase II trial.

The phase II trial, dubbed C-WORTHY Study, is evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor.

MRK closed Wednesday's trading at $56.88, down 0.32%.

Navidea Biopharmaceuticals Inc.'s (NAVB) yet another Supplemental New Drug Application, or sNDA, for the proposed expanded label for Lymphoseek Injection has been accepted for review by FDA, with a decision date set for October 16, 2014. This sNDA is aimed at expanding the Lymphoseek label to support more flexible utilization practices for Lymphoseek in lymphatic mapping and lymphoscintigraphy imaging.

Lymphoseek is currently approved for use in lymphatic mapping procedures performed to aid in the diagnostic evaluation of lymph nodes draining a primary tumor in patients with breast cancer and melanoma.

The company's first sNDA for Lymphoseek, seeking approval for use as a sentinel lymph node detection agent in patients with head and neck cancer is under Priority Review by the FDA, with a decision date of June 16, 2014.

NAVB closed Wednesday's trading at $1.85, down 3.14%. However, in after-hours, the stock was up 3.24% to $1.91.

Tekmira Pharmaceuticals Corp. (TKMR) rose more than 29% to touch a high of $25.40 on Wednesday before closing at $24.92, following encouraging regulatory news for its investigational anti-Ebola viral therapeutic, TKM-Ebola.

TKM-Ebola, which is under phase I testing, has been assigned Fast Track designation by the FDA. The U.S. Department of Defense is funding the development of TKM-Ebola.

The Ebola virus can cause severe viral haemorrhagic fever outbreaks in humans with a case fatality rate of up to 90%, according to the World Health Organization.

In extended trading, TKMR gained another 9.55% to $27.30.